The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a proteasome inhibitor, a glucocorticoid, an arsenic-containing compound, and ascorbic acid or a derivative thereof provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or relapsed hematologic disorders.

The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.

The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

The present invention is directed to methods of treating cancer and inhibiting proliferation of cancer cells with compositions comprising extracts prepared from Terminalia chebula fruits (for instance AyuFlex®), Terminalia bellerica fruits (for instance Ayuric®), Phyllanthus emblica fruits (for instance Capros®), Withania somnifera roots and leaves (for instance Sensoril®), Shilajit (for instance PrimaVie®), Azadirachta indica leaves and twigs (for instance PhytoBGS®), and/or combinations thereof, including a trivalent chromium complex with extracts of Shilajit and P. emblica (e.g. Crominex-3+®). Combinations of the extracts with anti-cancer drugs, and related methods, are also described.

The present invention is directed to methods of treating cancer and inhibiting proliferation of cancer cells with compositions comprising extracts prepared from Terminalia chebula fruits (for instance AyuFlex®), Terminalia bellerica fruits (for instance Ayuric®), Phyllanthus emblica fruits (for instance Capros®), Withania somnifera roots and leaves (for instance Sensoril®), Shilajit (for instance PrimaVie®), Azadirachta indica leaves and twigs (for instance PhytoBGS®), and/or combinations thereof, including a trivalent chromium complex with extracts of Shilajit and P. emblica (e.g. Crominex-3+®). Combinations of the extracts with anti-cancer drugs, and related methods, are also described.

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.

The present disclosure relates to a combination of an arsenic compound and a metal ion, for use as a medicament, wherein the metal ion increases the therapeutic effects of arsenic.